Individual lifetime benefit from low-dose colchicine in patients with chronic coronary artery disease.

Pascal M Burger,Jannick A N Dorresteijn,Aernoud T L Fiolet,Stefan Koudstaal,John W Eikelboom,Stefan M Nidorf,Peter L Thompson,Jan H Cornel,Charley A Budgeon, Iris C D Westendorp, Driek P W Beelen,Fabrice M A C Martens,P Gabriel Steg,Folkert W Asselbergs,Maarten J Cramer,Martin Teraa,Deepak L Bhatt,Frank L J Visseren,Arend Mosterd

European journal of preventive cardiology（2023）

引用 1|浏览13

暂无评分

摘要

The absolute benefits of low-dose colchicine vary between individual patients with chronic CAD. They may be expected to be of at least similar magnitude to those of intensified LDL-c and SBP reduction in a majority of patients already on conventional lipid-lowering and blood pressure-lowering therapy.

查看译文

关键词

coronary artery,low-dose

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要